SCHEMBL21252166

SCHEMBL21252166

O=C1c2ccccc2C(=O)N1[C@H]1CCOC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP1A2 P05177 2/20 0.42
CHRM2 P08172 1/20 0.42
OPRM1 P35372 1/20 0.42
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
IKZF3 Q9UKT9 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
IL4I1 Q96RQ9 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20331989 1.00 TSHR (0.42) TSHRALDH1A1CYP1A2CHRM2OPRM1
SCHEMBL31513601 0.90 CYP1A2 (0.45) TSHRALDH1A1CYP1A2CHRM2OPRM1
SCHEMBL21386681 0.89 L3MBTL1 (0.48) TSHRALDH1A1CYP1A2CHRM2OPRM1
SCHEMBL13016506 0.87 IL4I1 (0.35) ALDH1A1IL4I1HPGDHSD17B10
SCHEMBL29928113 0.81 TSHR (0.41) TSHRALDH1A1CYP1A2CHRM2OPRM1
SCHEMBL9625796 0.78 L3MBTL1 (0.54) TSHRALDH1A1CYP1A2CHRM2OPRM1
SCHEMBL2665681 0.78 L3MBTL1 (0.54) TSHRALDH1A1CYP1A2CHRM2OPRM1
SCHEMBL13016520 0.77 ALDH1A1 (0.40) TSHRALDH1A1CYP1A2TDP1LMNA
SCHEMBL15260892 0.77 TSHR (0.39) TSHRALDH1A1CYP1A2CHRM2OPRM1
SCHEMBL15261513 0.77 TSHR (0.39) TSHRALDH1A1CYP1A2CHRM2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2021-05-18 US disclosed
EP-3543227-B1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) 2020-12-30 EP disclosed
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2020-02-27 US disclosed
EP-3524603-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2019-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof FGFR4, FGFR1, FGFR2 TSHR 2198/4885ALDH1A1 993/4885CYP1A2 1183/4885
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF FGFR4, FGFR1, FGFR2 TSHR 2198/4885ALDH1A1 993/4885CYP1A2 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.